Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma in a Patient with Common Variable Immunodeficiency Syndrome

Reichenberger, Frank; Wyser, C; M, Gonon; Cathomas, Gieri; Tamm, Michael

doi:10.1159/000050475

Cited by 39 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increasing sputum purulence has been clearly associated with bacterial growth in sputum samples (Allegra et al 2005; Blasi et al 2006). Measurement of serum procalcitonin levels have recently been suggested to define AECOPD patients with a higher likelihood of bacterial infection (Reichenberger et al 2001; Christ-Crain et al 2004). Hence, the available data suggest that antimicrobial therapy provides benefit in carefully selected patients with more severe disease and more severe exacerbations.…”

Section: Macrolides In Copdmentioning

confidence: 99%

Role of macrolide therapy in chronic obstructive pulmonary disease

Martínez

Curtis

Albert

2008

COPD

105

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability worldwide. The Global Burden of Disease study has concluded that COPD will become the third leading cause of death worldwide by 2020, and will increase its ranking of disability-adjusted life years lost from 12th to 5th. Acute exacerbations of COPD (AECOPD) are associated with impaired quality of life and pulmonary function. More frequent or severe AECOPDs have been associated with especially markedly impaired quality of life and a greater longitudinal loss of pulmonary function. COPD and AECOPDs are characterized by an augmented infl ammatory response. Macrolide antibiotics are macrocyclical lactones that provide adequate coverage for the most frequently identifi ed pathogens in AECOPD and have been generally included in published guidelines for AECOPD management. In addition, they exert broad-ranging, immunomodulatory effects both in vitro and in vivo, as well as diverse actions that suppress microbial virulence factors. Macrolide antibiotics have been used to successfully treat a number of chronic, infl ammatory lung disorders including diffuse panbronchiolitis, asthma, noncystic fi brosis associated bronchiectasis, and cystic fi brosis. Data in COPD patients have been limited and contradictory but the majority hint to a potential clinical and biological effect. Additional, prospective, controlled data are required to defi ne any potential treatment effect, the nature of this effect, and the role of bronchiectasis, baseline colonization, and other cormorbidities.

show abstract

Section: Macrolides In Copdmentioning

confidence: 99%

Role of macrolide therapy in chronic obstructive pulmonary disease

Martínez

Curtis

Albert

2008

COPD

105

View full text Add to dashboard Cite

show abstract

“…Spleen enlargement was also present in our patient, another typical symptom of CVID. Malignant lymphoproliferative diseases are reported as complications of CVID, namely different histological entities of Non-Hodgkin lymphoma (for overview see [12]), lymphoma of the CNS [13], gastrointestinal tract [14], lung [15], T cell lymphoma [16], and also Hodgkin's disease [17,18] develops in some patients. The BCL6 overexpression in the immunohistology is of note since CVID related lymphomas are reported to be associated with mutations and rearrangements of BCL6 [19].…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barre-Strohl Syndrome Unraveled as Paraneoplastic Syndrome of B-cell Acute Lymphoblastic Leukemia in a Patient with Preceding Common Variable Immunodeficiency Syndrome with Evans Syndrome

Mailänder

Gleisner

Blau

et al. 2004

Leukemia & Lymphoma

View full text Add to dashboard Cite

A 26-year-old man with a history of common variable immunodeficiency and Evans syndrome (immunthrombocytopenia and immunhemolytic anemia) with sarcoid like lesions and lymph node enlargements in the previous history is described. The patient presented with symptoms resembling Guillain-Barre-Strohl as paraneoplastic syndrome just before the diagnosis of acute lymphoblastic leukemia of the L3 type. The patient was treated according to the B-ALL protocol of the German ALL study group and achieved a complete response after six cycles of chemotherapy together with a resolution of all neurologic symptoms.

show abstract

“…Biopsies may be necessary for the diagnosis of ILD in PAD and to differentiate pulmonary nodules from malignancies, particularly lymphomas, which may arise in the lungs of these patients. 106 Pulmonary function testing may reveal obstructive pathology, particularly in PAD patients with bronchiectasis, or restrictive lung disease resulting in reductions of forced vital capacity (FVC) and/or diffusing capacity for carbon monoxide (DLCO) as a consequence of ILD. 86, 107 Significant decrease of DLCO may precede decline of FVC in PAD patients with ILD, and therefore should be included in pulmonary function assessment of these patients.…”

Section: Interstitial Lung Diseasementioning

confidence: 99%

Lung Disease in Primary Antibody Deficiencies

Schussler

Beasley

Maglione

2016

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Primary antibody deficiencies (PADs) are the most common form of primary immunodeficiency and predispose to severe and recurrent pulmonary infections which can result in chronic lung disease including bronchiectasis. Chronic lung disease is among the most common complications of PAD and a significant source of morbidity and mortality for these patients. However, the development of lung disease in PAD may not be solely the result of recurrent bacterial infection or a consequence of bronchiectasis. Recent characterization of monogenic immune dysregulation disorders and more extensive study of common variable immunodeficiency has demonstrated that interstitial lung disease (ILD) in PAD can result from generalized immune dysregulation and frequently occurs in the absence of pneumonia history or bronchiectasis. This distinction between bronchiectasis and ILD has important consequences in the evaluation and management of lung disease in PAD. For example, treatment of ILD in PAD typically utilizes immunomodulatory approaches in addition to immunoglobulin replacement and antibiotic prophylaxis which are the stalwarts of bronchiectasis management in these patients. Additionally, while all antibody deficient patients are at risk of developing bronchiectasis, ILD occurs in some forms of PAD much more commonly than others, suggesting that distinct but poorly understood immunological factors underlie development of this complication. Importantly, ILD can have earlier onset and may worsen survival more than bronchiectasis. Further efforts to understand the pathogenesis of lung disease in PAD will provide vital information for the most effective methods of diagnosis, surveillance, and treatment of these patients.

show abstract

Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma in a Patient with Common Variable Immunodeficiency Syndrome

Cited by 39 publications

References 15 publications

Role of macrolide therapy in chronic obstructive pulmonary disease

Role of macrolide therapy in chronic obstructive pulmonary disease

Guillain-Barre-Strohl Syndrome Unraveled as Paraneoplastic Syndrome of B-cell Acute Lymphoblastic Leukemia in a Patient with Preceding Common Variable Immunodeficiency Syndrome with Evans Syndrome

Lung Disease in Primary Antibody Deficiencies

Contact Info

Product

Resources

About